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Background: Aneuploidy is a feature of most cancer cells that is often accompanied by an elevated rate of
chromosome mis-segregation termed chromosome instability (CIN). While CIN can act as a driver of cancer
genome evolution and tumor progression, recent findings point to the existence of a threshold level beyond which
CIN becomes a barrier to tumor growth and therefore can be exploited therapeutically. Drugs known to increase
CIN beyond the therapeutic threshold are currently few in number, and the clinical promise of targeting the CIN
phenotype warrants new screening efforts. However, none of the existing methods, including the in vitro
micronuclei (MNi) assay, developed to quantify CIN, is entirely satisfactory.
Methods: We have developed a new assay for measuring CIN. This quantitative assay for chromosome mis-
segregation is based on the use of a non-essential human artificial chromosome (HAC) carrying a constitutively
expressed EGFP transgene. Thus, cells that inherit the HAC display green fluorescence, while cells lacking the HAC
do not. This allows the measurement of HAC loss rate by routine flow cytometry.
Results: Using the HAC-based chromosome loss assay, we have analyzed several well-known anti-mitotic, spindle-
targeting compounds, all of which have been reported to induce micronuclei formation and chromosome loss. For
each drug, the rate of HAC loss was accurately measured by flow cytometry as a proportion of non-fluorescent cells
in the cell population which was verified by FISH analysis. Based on our estimates, despite their similar cytotoxicity,
the analyzed drugs affect the rates of HAC mis-segregation during mitotic divisions differently. The highest rate of
HAC mis-segregation was observed for the microtubule-stabilizing drugs, taxol and peloruside A.
Conclusion: Thus, this new and simple assay allows for a quick and efficient screen of hundreds of drugs to
identify those affecting chromosome mis-segregation. It also allows ranking of compounds with the same or similar
mechanism of action based on their effect on the rate of chromosome loss. The identification of new compounds
that increase chromosome mis-segregation rates should expedite the development of new therapeutic strategies to
target the CIN phenotype in cancer cells.
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An abnormal chromosome number (aneuploidy) is a
feature of most solid tumors and is often accompanied by
an elevated rate of chromosome mis-segregation termed
chromosome instability (CIN) [1]. The gain or loss of entire
chromosomes leads to large-scale changes in gene copy
number and expression levels. The molecular mechanisms
underlying CIN include defects in chromosome cohesion,
mitotic checkpoint function, centrosome copy number,
kinetochore-microtubule attachment dynamics, and
cell-cycle regulation. While CIN can act as a driver of
cancer genome evolution and tumor progression, recent
findings point to the existence of a threshold level beyond
which CIN becomes a barrier to tumor growth, and
therefore, it can be exploited therapeutically. Janssen
and co-authors [2] have analyzed the consequences of
gradual increases in chromosome segregation errors
on the viability of tumor cells and normal human fibro-
blasts. Partial reduction of essential mitotic checkpoint
components in tumor cell lines caused mild chromosome
mis-segregation, but no lethality. These cells were, however,
much more sensitive to low doses of taxol, which enhances
the amount and severity of chromosome segregation errors.
Sensitization to taxol was achieved by reducing the levels of
Mps1 or BubR1, proteins with dual roles in checkpoint
activation and chromosome alignment. Importantly,
untransformed human fibroblasts with reduced Mps1 levels
could not be sensitized to sub-lethal doses of taxol. Thus,
targeting the mitotic checkpoint and chromosome
alignment simultaneously may selectively kill tumor
cells. In another study [3], a set of genes was identified
that are repressed in response to taxol treatment and
over-expressed in tumors exhibiting CIN. The silencing of
these genes caused cancer cell death, suggesting that these
genes might be involved in the survival of aneuploid cells.
In diploid cells, but not in chromosomally unstable
cells, taxol causes the repression of CIN-survival genes,
followed by cell death. Taking into account the fact that
aneuploidization per se seems to be a very inefficient path
towards cancer and additional hits are necessary for the
generation of a cancer cell ([4] and references therein),
these and other studies [5,6] indicate that increased
destabilization of chromosomes might push genetically
unstable cancer cells towards death, whereas more stable
normal cells would be able to tolerate such insults.
Elevation of CIN as an approach to cancer therapy is
attracting considerable attention [2-5]. However, none
of the methods used to study CIN and its induction
by environmental agents is entirely satisfactory. Karyotype
analysis is bedeviled by the karyotypic variation already
often present in cancer cell lines. Micronucleus assays
(MNi) are widely used to detect broken or lagging chro-
mosomes, but fail to detect non-balanced chromosome
segregation [7].In this study, we developed a new assay for meas-
uring CIN. This quantitative assay for chromosome
mis-segregation is based on the use of the human artificial
chromosome (HAC) constructed in our lab earlier as a
gene therapy tool for the efficient and regulated expression
of genes of interest [8-10]. The HAC contains centromeric
repeats that form a functional centromere/kinetochore,
allowing its stable inheritance as a nonessential chromo-
some, albeit with a loss rate roughly 10× that of the native
chromosomes [11,12]. To adopt this HAC for CIN studies,
an EGFP transgene was inserted into the HAC. This
allowed the measurement of the HAC loss rate by routine
flow cytometry. Thus, the HAC offers a sensitized
and simple system to measure CIN, particularly after
drug treatment. In this study, the HAC-based CIN
assay has been verified using a set of well-known
aneugens and clastogens. This new assay has the potential
to be developed for high-through put screening methods to
identify new compounds that elevate chromosome
mis-segregation and drive lethal aneuploidy. New and
potentially less toxic agents that selectively elevate CIN in
cancer cells to promote cancer cell death identified with
this new screening tool could lay the foundation for new
treatment strategies for cancer.
Methods
Cell lines
Human fibrosarcoma HT1080 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen)
supplemented with 10% (v/v) tet system-approved fetal
bovine serum (Clontech Laboratories, Inc.) at 37°C in 5%
CO2. Hypoxanthine phosphoribosyltransferase (HPRT)-
deficient Chinese hamster ovary (CHO) cells (JCRB0218)
carrying the alphoidtetO-HAC were maintained in Ham's
F-12 nutrient mixture (Invitrogen) plus 10% FBS with
8 μg/ml of BS (Funakoshi). After loading of the EGFP
transgene cassette into the alphoidtetO-HAC, the CHO
cells were cultured in 1× HAT supplemented medium.
Loading of the EGFP transgene cassette into the loxP site
of alphoidtetO-HAC in CHO cells
A total of 3 to 5 μg of a EGFP transgene plasmid
(or X3.1-I-EGFP-I described previously [13]) and 1
to 2 μg of the Cre expression pCpG-iCre vector
DNA were co-transformed into HPRT-deficient CHO
cells containing the alphoidtetO-HAC by lipofection
with FuGENERHD transfection reagent (Roche) or
Lipofectamine 2000 (Invitrogen). HPRT-positive colonies
were selected after 2 to 3 weeks growth in HAT medium.
For each experiment, from 5 to 7 clones were usually
selected. Correct loading of the EGFP transgene cassette
into the HAC was confirmed by genomic PCR with a
specific pair of primers that diagnose reconstitution of the
HPRT gene [9].
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The alphoidtetO-HAC containing the EGFP transgene
cassette (EGFP-HAC) was transferred from CHO cells
to HT1080 cells using a standard microcell-mediated
chromosome transfer (MMCT) protocol [13,14]. Blasticidin
(BS) was used to select resistant colonies containing the
HAC. Typically, three to ten BSR colonies were obtained in
one MMCT experiment. BSR colonies were analyzed by
FISH for the presence of the autonomous form of
the HAC. The co-transfer of CHO chromosomes was
examined using a sensitive PCR test for rodent-specific
SINE elements [9].
Flow cytometry
Analysis of EGFP expression was performed on a FACS
Calibur instrument (BD Biosciences) using CellQuest
acquisition software and analyzed statistically with
FlowJo software [15,16]. The cells were harvested by
trypsin-treatment. Intensities of fluorescence were
determined by flow cytometry. A minimum of 4 x 104
cells was analyzed for each cell sample.
Drug treatment
Nine different drugs were used in our experiments (Table 1).
Our experiment protocol was as follows. HT1080 cells
containing the EGFP-HAC were maintained on blasticidin
selection to select for the presence of the HAC. Approxi-
mately 1 × 105 cells were cultured either in the presence or
absence of blasticidin selection in parallel with a third
culture that was exposed to the agent under examination to
test its effect on EGFP-HAC segregation. The drug concen-
tration applied was adjusted to the IC50 level for each
compound which was determined using a proliferation
assay described below. Concentrations of drugs and lengthsTable 1 Drugs used in this study
Drug Target Concentration/
time treatment
Fold increase of HAC
loss per cell division
Microtubule-stabilizing drugs
Taxol Beta-tubulin 10 nM-overnight x 47
Ixabepilone Beta-tubulin 100 nM-overnight x 31
Docetaxel Beta-tubulin 10 nM-2 hrs x 10
Peloruside A Beta-tubulin 100 nM-overnight x 32
Microtubule-depolymerizing drugs
Nocodazole Beta-tubulin 1 μM-overnight x 8
Other drugs
SAHA HDAC 5 μM-overnight x 1
VP16
(etoposide)
TOP2 8 μM-2hrs x 7
Reversine Aurora B,
MPS1
1 μM-3 days x 14
ZM-447439 Aurora B 1 μM-3 days x 29of treatment are presented in Table 1. Subsequently, the
drug was removed by performing three consecutive
medium washes and the cells were subsequently
grown without blasticidin selection for 1–14 days. At
the end of the experiment, cells were collected and
analyzed by flow cytometry to detect the proportion
of cells that retain EGFP fluorescence. This served as a
measure of EGFP-HAC stability following drug treatment.
For taxol and peloruside A, nine independent measuring of
EGFP-HAC loss were carried out. The results were repro-
ducible and the std were small (peloruside A: SD±0.9%,
taxol: SD±1.1%). Therefore, for other drugs, experiments
were carried out in triplicate.
Calculation of the rate of HAC loss after drug treatment
The formula, Pn = P0(1 − R)
n [17], routinely used to calcu-
late the rate (R) of spontaneous HAC (or chromosome)
loss, cannot be applied when cells are treated by a single
dose of drug. So in our study, we first determined the
normal rate of spontaneous HAC miss-segregation
(RNormal) in the host cell line HT1080 using the formula,
Pnormal ¼ P0 2−RNormal2
 n1 (Figure 1); where P0 is the percent-
age of EGFP(+) cells at the start of the experiment as deter-
mined by FACS. These cells were cultured under HAC
selection conditions using blaticidin. PNormal is the percent-
age EGFP(+) cells after culturing without HAC selection
(no blasticidin) for a duration of t1. In this study t1 was 14
days. n1 is the number of cell doublings that occurs during
culturing without blasticidin selection. The doubling
time of HT1080 under normal growth conditions is
approximately 18 hours. The number of cell divisions
(n) is calculated by (t / host cell doubling time).
Once (RNormal) was obtained, the rate of HAC loss
induced by drug treatment (RDrug) is then determined
using the formula, PTreated ¼ P0 2−RDrug2
 n2 2−RNormal
2
 n3 .
Justification of this algorithm is presented in Figure 1.
As before, P0 represents the percentage of EGFP(+)
cells at the start of the experiment, cultured under
HAC selection condition. PTreated is the percentage of
EGFP(+) cells at the end of a drug treatment experiment
with a duration of (t2 + t3), where t2 is the duration of
drug treatment and t3 is the duration of culturing after the
drug is removed. (t2 + t3) was 14 days in this study. n2 is
the number of cell doublings that occurs during drug
treatment, while n3 is the number of cell doublings that
occurs during the culturing without selection after
drug treatment.
In the present study, the duration of most drug treat-
ments were less than the duration of a single cell cycle of
HT1080 (t2 <18 hr). We made the assumption that
any significant increase in HAC loss occurs only during
the first mitotic division after washing off a drug (n2 = 1).
Thus n3 = (14 d / 18 hr - 1). The exceptions, reversine and
Figure 1 (See legend on next page.)
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Figure 1 Calculation of the rate of HAC miss-segregation induced by drug treatment. Justification of the algorithm describing the
dynamics of the accumulation of HAC-less cells caused by a single dose of chromosome-destabilizing compounds. This mathematical model
assumes: 1) the drug kills cells non-selectively; 2) the drug’s effect on HAC mis-segregation is not persistent and limited to the cell cycle when it
is present; 3) spontaneous HAC loss after drug exposure does not change; 4) the HAC does not confer a selective advantage or disadvantage; 5)
the cells are growing synchronously and 6) there is one HAC per cell. Assumptions 2) and 3) have been confirmed experimentally (see Additional
file 1). (A) Our model assumes that when mis-segregation occurs during mitosis, one daughter cell will inherit a HAC while the other daughter
cell does not. (B) Illustrated model of HAC lost in a population of cells. (C) Derivation of the general equation for HAC miss-segregation rate. x is
the number of cells which are EGFP(+); y is the number of cell which are GFP(−); R is the probability of HAC miss-segregation; n is the number of
cell divisions; P0 is the proportion of EGFP(+) cell at generation F0; P1 is the proportion of EGFP(+) cell at generation F1. (D) Calculation of rates
(see Methods for more details).
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despite the 3 day drug treatment only one cell division is
assumed to have occurred. We also assumed that HAC
stability in subsequent cell divisions is no different from
that of untreated cells.
The algorithm we used is valid between the ranges
of 0 to 1. R values large than 1 indicate that the
assumptions made in this model are incorrect. The
assumption of synchronous growth in the model
means that the estimated mis-segregation rate is
lower than real values. As the spontaneous rate of
HAC mis-segregation (RNormal) was found to be low,
this algorithm is relatively insensitive to the number
of cell divisions that occurs post drug treatment. It is
worth noting that the frequency of HAC loss in the clones
carrying two copies of the HAC is indistinguishable from
those containing a single copy of the HAC (data not
shown). Therefore, the model is applicable when a cell
inherits two copies of the HAC due to non-disjunction.
Cell viability test
MTS tetrazolium cell viability assays were done
according to the manufacturer’s instructions (CellTiter
96 AQueous Assay reagent; Promega). Briefly, the
CellTiter 96 AQueous One Solution Reagent was
added to each well and incubated at 37°C for 3 h.
Cell proliferation was determined by measuring the
absorbance at 490 nm using a microtiter plate reader
(Molecular Devices, Sunnyvale, CA). The half-maximal
inhibitory concentration (IC50) was obtained from the
MTS viability curves using GraphPad Prism 5. Experiments
were carried out in triplicate.
FISH analysis with PNA probes
The presence of the HAC in an autonomous form was
confirmed by FISH analysis as previously described [8,9].
HT1080 cells containing the HAC were grown in
DMEM medium to 70-80% confluence. Metaphase cells
were obtained by adding colcemid (Gibco) to a final
concentration of 0.05 μg/ml and incubating overnight.
Media was aspirated, and the plate washed with 1x PBS.
Cells were removed from the plate by 0.25% Typsin,
washed off with DMEM, pelleted and resuspended in 10ml of 50 mM KCl hypotonic solution for 30 min at 37°C.
Cells were fixed by three washes of fixative solution (75%
acetic acid, 25% methanol). Between each wash, cells
were pelleted by centrifugation at 900 rpm for 4 min.
Metaphase cells were evenly spread on a microscope
slide and the fixative solution evaporated over boil-
ing water. Dry slides were rehydrated with 1× PBS
for 15 min, and fixed in 4% formaldehyde-1× PBS
for 2 min, followed by three 5 min 1× PBS washes
and ethanol series dehydration. PNA (peptide nucleic
acid) labeled probes used were telomere (CCCTAA)3-Cy3)
(PerSeptive Biosystems, Inc.) and tetO-alphoid array
(FITC-OO-ACCACTCCCTATCAG) (Panagene, South
Korea). Ten nanomol of each PNA probe was mixed
with hybridization buffer and applied to the slide,
followed by denaturation at 80°C for 3 min. Slides
were hybridized for 2 hours at room temperature in
the dark. Slides were washed twice in 70% formamide,
10 mM Tris pH 7.2, 0.1% BSA and followed by three
washes with 1xTBS, 0.08% Tween-20. Slides were
dehydrated gradually with a series of 70%, 90% and 100%
ethanol washes and mounted (Vectorshield with DAPI).
Images were captured using a Zeiss Microscope (Axiophot)
equipped with a cooled-charge-coupled device (CCD)
camera (Cool SNAP HQ, Photometric) and analyzed
by IP lab software (Signal Analytics). The PNA-DNA
hybrid probes demonstrated a high hybridization efficiency,
staining intensity and adopt a stable duplex form with
complementary nucleic acid.
FISH analysis with the BAC probe
HT1080 cells were processed for fluorescence in situ
hybridization (FISH) after drug treatment followed by the
14 day washout. The probe used for FISH was BAC32-
2-mer(tetO) DNA containing 40 kb of alphoid-tetO array
cloned into a BAC vector as described previously [8].
Specifically, a BAC32-2-mer(tetO) clone contains an
amplified synthetic alphoid DNA dimer. One monomer of
this dimer is an alphoid DNA consensus sequence
carrying the tetO sequence; another monomer is
alphoid DNA from chromosome 17. This probe is
specific to the HAC but also gives a low signal with centro-
meric regions of several endogenous chromosomes. BAC
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with digoxigenin-11dUTP or biotin16-dUTP (Roche
Diagnostics). Images were captured as before. The
probe was denatured for 5 min at 95°C and added to
the slides, which were incubated at 72°C for 2 min
before overnight incubation at 39°C. After washes
with 0.1 × SSC at 65°C followed by a wash with 4 ×
SSC + 0.1% Tween 20 at room temperature, standard
procedures were used to detect biotinylated probes. Slides
were mounted with VectaShield and screened for the pres-
ence or absence of the HAC. Between 70–250 metaphases
were analyzed for each experiment (one drug treatment).Genomic DNA preparation and PCR analysis
Genomic DNA for PCR analysis was prepared using
a QIAmp DNA Mini Kit (QIAGEN Inc., Valencia,
CA, USA). Reconstitution of the HPRT gene after
Cre/lox-mediated recombination was determined by
specific primers, Lox137-R 5′-agccttctgtacacatttcttctc-
3′ and Rev #65′-gctctactaagcagatggccacagaactag-3′. Cross
contamination by hamster chromosomes was determined
by specific primers detecting hamster SINEs: Cons
B2 5′-ccatctgtaatgagatctgatgc-3′, Ham B2-F 5′-gctc
agaggttaagagcactgac-3′ and Ham B2-R 5′-tgcttccat
gtatatctgcacac-3′. PCR products for sequencing were
separated by agarose gel electrophoresis and gel
extracted.Micronucleus formation assay (MNi)
Duplicate cultures of cells were exposed to different
compounds or DMSO control. Micronuclei formation
was assessed by phase contrast microscopy in Table 2
after 20 hours. In the time course assay (Additional file 1),
cells were harvested after 20 h treatment and grown in
compound-free medium for 24 h, 5 days and 10 days
then placed on chamber slides. Dihydrocytochalasin
B was added for 90 min to permit formation of cyto-
kinesis blocked cells. Cells were washed with PBS
and incubated with 0.075 M KCl then fixed in ice
cold 3:1 v/v methanol: acetic acid and dried under
vacuum. The frequency of micronucleated cells wasTable 2 Micronuclei (MNi) formation in the HAC-containing
HT1080 cells treated by different drugs
Drug Fraction of cells with MNi Mean ± SD (%)**
Exp. 1 Exp. 2
Vehicle* 3% 1% 2 ± 1
10 nM Taxol 43% 37% 40 ± 3
100 nM Peloruside A 74% 63% 69 ± 5
1 μM ZM447439 56% 57% 57 ± 1
100 nM Nocodazole 50% 56% 53 ± 3
*Vehicle: 0.01% DMSO (this was the highest amount of DMSO used).
** Number of MN is given as means ± SD in two independent experiments.assessed as described in [18] using DAPI staining
and fluorescence microscopy.Results
Experimental design for identification of drugs that
elevate CIN in cancer cells
Figure 2 shows a general scheme of the new assay
developed for measuring chromosome instability (CIN)
based on the use of a human artificial chromosome (HAC)
carrying the EGFP (enhanced green fluorescence protein)
transgene. Due to the presence of a functional kinetochore,
the EGFP-HAC is maintained as a non-essential 47th
chromosome that replicates and segregates like a normal
chromosome in human cells. Thus, the cells that inherit
the HAC display green fluorescence, while cells that lack it
do not. Normally, after growing in non-selective medium
(i.e. in the absence of selection for the HAC), the majority
of cells contain one copy of the HAC. After drug
treatment, there are two possibilities: either no
change in the EGFP level (no response to the drug)
or an increased percentage of cells without HAC due
to HAC segregation or replication errors (response to
the drug treatment). It is expected that the control
untreated cells should show uniform green fluorescence,
while those that have lost HAC after drug treatment
will exhibit reduced fluorescence that can be detected
by flow cytometry.Construction of the HAC carrying a single copy of the
EGFP transgene and its transfer to human cells
The EGFP transgene cassette (X3.1-I-EGFP-I) was
described previously [13]. To adapt the alphoidtetO-HAC
[8] for CIN studies, the EGFP transgene cassette was
inserted into a single loxP loading site of the HAC [13] in
hamster HPRT-deficient Chinese Hamster Ovary (CHO)
cells (Figure 3A, B, 2B). In this cassette, EGFP is flanked by
the cHS4 insulator sequences to protect the transgene from
epigenetic silencing. Targeting of the EGFP-cHS4 cassette
into the loxP site was accompanied by reconstitution of the
HPRT gene, allowing cell selection on HAT medium.
Therefore, recombinant clones were selected by
growth in HAT medium after two-three weeks. PCR
analysis with specific primers (see Methods) confirmed
that the HPRT gene was indeed reconstituted in all five
drug-resistant clones analyzed (data not shown). The effi-
ciency of cassette targeting into the HAC was <1-3 × 10−4.
All of the HPRT+ transfectants expressed the EGFP trans-
gene, which was detected by fluorescence microscopy.
FISH analysis of CHO metaphase spreads revealed the
HAC in an autonomous form in four clones (data not
shown). One clone containing the HAC was chosen for
further experiments.
Figure 2 Scheme of an assay for measuring chromosome instability (CIN) based on the use of HAC containing the EGFP transgene.
Cells that inherit the HAC display green fluorescence, while cells that lack it do not. It is expected that the control untreated cells should show
uniform green fluorescence, while those that have lost HAC after drug treatment should be highly variable in fluorescence. Therefore, the actual
number of cells with the EGFP-HAC can be measured by FACS. Thus, the compounds, which increase HAC loss and therefore increase
spontaneous chromosome mis-segregation rates, may be identified.
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from CHO to human HT1080 fibrosarcoma cells via
microcell-mediated chromosome transfer (MMCT).
Recipient cells were selected using the BS resistance
gene on alphoidtetO-HAC [8]. Ten BS-resistant clones
that expressed the EGFP transgene were isolated from
one MMCT experiment and analyzed using PCR with
hamster-specific primers (see Methods) to rule out
co-transfer of hamster chromosomes after MMCT.
Fluorescence images of HT1080 cells carrying the
HAC with the EGFP cassette are shown (Figure 3C).
FISH analysis showed that the HAC was maintained
autonomously without any detectable integration into the
host genome in three out of five randomly selected
clones. One clone (clone 12) containing an autono-
mously propagated EGFP-HAC was chosen for further
analysis (Figure 3D). Based on the results from FISH
analysis, the rate of spontaneous HAC loss was 7 x 10-3
per cell division. The rate of HAC loss measured by
the accumulation of non-fluorescent cells during
growth in the absence of selection for the HAC by
FACS was very similar, 13 × 10-3 (Table 3), suggesting
that non-fluorescent cells arise primarily through loss
of the EGFP-marked HAC. Notably, mitotic stability of
the EGFP-HAC is approximately 10-fold less than sta-
bility of natural chromosomes in HT1080 cells (~1 ×
10-3) [11,12], making the system more sensitive for the
detection of mis-segregation events. It is worth noting
that in this clone, EGFP expression was stable for at
least twelve months under selective conditions (data
not shown). Based on these results, we conclude that
the EGPF transgene on the HAC is stably expressed and
that cells offer a sensitized system for analyzing chromo-
some loss.Effect of aneugens and clastogens on the rate of HAC
mis-segregation during mitotic divisions
We next investigated whether the EGFP/HAC-based assay
could be used to detect compounds that cause chromosome
loss and mis-segregation. HT1080 cells with an autono-
mously propagated EGFP-HAC were treated with eight
known aneugens: taxol (pacilitaxel), docetaxel, peloruside A,
ixabepilone, nocodazole, ZM447439, reversine, and SAHA
(Table 1). Taxol, docetaxel, peloruside A, ixabepilone,
and nocodazole are microtubule-targeting drugs [19];
ZM447439 and reversine are inhibitors of Aurora B
and MPS1, respectively, and function in the spindle
assembly checkpoint [20,21]. SAHA is an inhibitor of
histone deacetylases (HDAC) [22]. Cells were also treated
with the well-known clastogenic DNA topoisomerase II
inhibitor VP16 (etoposide) [23].
For each compound, a cell cytotoxicity assay was
carried out to determine IC50 values, i.e., the conditions
under which the viability of cells would be around
50%. We chose this parameter in order to normalize
the results at the same percentage of viable cells. The
evaluation of chromosome instability at the IC50 values
has been used in many studies involving micronucleus
scoring [24,25]. Time treatments and drug concentrations
corresponding to IC50 are summarized in Table 1. For all
compounds, the IC50 values were in the range clinically
relevant concentrations, where applicable. After treatment,
the cells were grown for two weeks in the absence of
selection. Samples were analyzed every few days, and
the proportion of non-fluorescent cells was determined.
Non-fluorescent cells could be detected after a few days,
and treated and untreated cell populations were clearly
distinguishable after 5–7 days. The delay between HAC
loss and the appearance of non-fluorescent cells is due to
Figure 3 Schematic diagram of construction of the alphoidtetO-HAC containing the EGFP transgene to measure chromosome
instability. (A) Three steps of MMCT to transfer the HAC. The original alphoidtetO-HAC was generated in human fibrocarcoma HT1080 cells [8].
The alphoidtetO-HAC was transferred to homologous recombination proficient chicken DT40 cells via MMCT. In chicken DT40 cells, a loxP gene
loading site was generated in the HAC [13]. The modified alphoidtetO-HAC was transferred to HPRT-deficient hamster CHO cells via MMCT.
(B) Loading of the EGFP-containing cassette into the HAC was carried out in hamster CHO cells. Insertion of the cassette into the loxP site of the
HAC by Cre/lox-mediated recombination is accompanied by reconstitution of the HPRT gene allowing the cells selection on the HAT medium.
This modified HAC was transferred back to human HT1080 cells via third round of MMCT. (C) Fluorescence images of cells carrying the HAC with
the EGFP cassette are shown. (D) FISH analysis of the HAC-containing HT1080 clone. The HAC was visualized using BAC32-2-mer(tetO) DNA
containing 40 kb of alphoid-tetO array cloned into a BAC vector as described previously [8] (red). Chromosomal DNA was counterstained with
DAPI. The HAC is indicated by arrowhead.
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high half-life. Based on our analysis, sampling time has a
broad interval (5–14 days) without a significant effect on
the calculated rate of HAC loss (see Additional file 1). In
most experiments, the cells were analyzed 14 days after
drug washout. Figure 4 shows representative flow cytome-
try histograms illustrating loss of fluorescence for the cells
treated by a single doze of taxol. It is important that the
measuring is highly reproducible: The raw FACS data of
three independent populations for drug treatments have
standard deviations less than 1%.
Figure 5 summarizes the estimated rates of HAC
loss in response to different drugs. The rate of HAC loss
(RDrug) induced by drug treatment was calculated from the
proportion of non-fluorescent cells in the population
(Table 3) using the formula P0
2−RDrug
2
 n2 2−RNormal
2
 n3
(see more details in Methods and Figure 1 legend).As seen, a single dose of taxol greatly increases (~50
times) the rate of HAC loss. Taxol (pacilitaxel) was isolated
~ 40 years ago and is currently administered in a large var-
iety of indications, including solid tumors and haemato-
logical malignancies [19] and references therein]. While its
mechanism of action remains controversial, accumulating
data suggest that at clinically relevant concentrations, taxol-
mediated cell death involves elevation of chromosome mis-
segregation that is incompatible with cancer cell survival
[26] and references therein]. HAC loss was also significantly
increased by peloruside A, ixabepilone, which also binds to
the microtubule as taxol, and by the Aurora B inhibitor
ZM-447439. For the other analyzed compounds except
SAHA, the rates of HAC loss were also increased com-
pared to controls, but much lower compared to those
obtained after taxol or peloruside A treatment. The lowest
increase of HAC loss was obtained after treatment by the
inhibitor of histone deacetylases, SAHA.
Table 3 Comparison between FISH and FACS data to
evaluate HAC induced by drug treatment
Drug FISH FACS Rate of HAC loss
% Cells
with HAC
% Cells
with EGFP
per cell division**
No drug 86 (100)* 85.1 ± 0.9 13 × 10-3
Taxol 59 (139) 59.5 ± 0.9 597 × 10-3
Ixabepilone 71 (116) 68.0 ± 0.1 396 × 10-3
Docetaxel 74 (101) 79.1 ± 1.8 133 × 10-3
Peloruside A 68 (71) 67.4 ± 0.9 411 × 10-3
Nocodazole 79 (77) 80.3 ± 0.9 107 × 10-3
SAHA 79 (160) 84.3 ± 1.2 12 × 10-3
VP16 (Etoposide) 86 (156) 80.7 ± 0.9 96 × 10-3
Reversine*** 77 (71) 79.0 ± 0.5 176 × 10-3
ZM-447439*** 75 (75) 70.4 ± 0.5 374 × 10-3
* In parentheses, the number of metaphases screened for the presence or
absence of the HAC.
** Rates of the HAC loss after drug treatment were calculated from FACS data
using the formula PTreated ¼ P0 2−RDrug2
 n2 2−RNormal
2
 n3 .
*** A real rate of HAC loss may be a little bit lower after treatment by
inhibitors of Aurora B and MPS1 because reversine and ZM-447439 do not
completely block cell divisions.
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chemical dose was investigated. Treatment of cells with
higher doses of the compounds kills more cells but does
not increase the rate of HAC loss. This may be explained if
cells arrest, then apoptosis in response to damage of the
spindle or if the daughter cells are not viable. We also
performed the experiments with lower doses of drugs, i.e.
with concentrations ½, ¼, 1/8 and
1/16 of the concentration
corresponding to IC50. For some drugs, the frequency of
HAC loss was dose independent while for others displayed
a linear dose-dependence. For example, HAC loss wasFigure 4 Two flow cytometry histograms illustrating mitotic stability
treatment by taxol. The x-axis represents the intensity of the fluorescence
positive cells. The results of triplicate experiments are shown.decreased in an almost linear fashion after treatment by
VP16 (which is inhibitor of TOP2) with lower doses. In
contrast, our analysis revealed a non-linear dose-dependent
decrease in HAC loss frequencies for nocodazole and taxol,
which were previously reported as compounds that interact
with the mitotic spindle (thresholded concentration-effect
response) [27].
FISH analysis was used to confirm that the appearance
of non-fluorescent cells detected by flow cytometry
corresponds to HAC loss events and to exclude possible
alternative explanations such as mutations in the EGFP
gene or its epigenetic silencing. Quantitative analysis of
metaphase chromosome spreads using a HAC-specific
probe (see Methods) correlated with the data on HAC loss
determined by FACS (Table 3). Therefore, we conclude
that the appearance of non-fluorescent cells is caused by
HAC loss.
An unexpected result was the different effects of
microtubule-binding drugs on HAC stability. Ixabepilone,
docetaxel, and peloruside A are microtubule-stabilizing
agents similar to taxol [19]. However, each drug exhibited
a different effect on HAC mitotic stability, suggesting a
different cell response to these compounds. Interestingly,
under these conditions, all of the analyzed drugs induced
micronuclei formation in the HAC-containing HT1080
cells (Table 2) similar to that reported for other cell
lines [27]. However, there was no detectable correlation
between frequencies of MNi formation (that varied between
37% and 63%) and rates of HAC loss determined by FISH
and FACS (Table 3). Thus, aneugens with a similar
mechanism of action and cytotoxicity may differ from
each other by their effect on the mitotic stability of
the non-essential human artificial chromosome. It isof the EGFP-HAC in HT1080 cells (A) before and (B) after
, the y-axis the number of cells. The bar stands for the amount of
Figure 5 Mitotic stability of the EGFP-HAC in HT1080 human cells treated by nine different drugs. A rate of HAC loss per generation was
calculated as described in Methods and Figure 1. Blue bars correspond to the frequency of HAC loss when the cells were treated by taxol and its
derivatives. The control corresponds to a frequency of spontaneous loss of the EGFP-HAC in human HT1080 cells.
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can detect such differences between the compounds. Based
on these results, we conclude that a newly developed
EGFP/HAC-based assay for measuring CIN is a more
sensitized system than other previously described methods
to detect chromosome mis-segregation.
Discussion
Targeting of CIN in cancer therapy requires measurement
of the accuracy of chromosome transmission. At present, a
variety of methods is used to study chromosome instability
(CIN) and its induction by environmental agents [7,28] and
references therein]. Because test systems screening for
numerical chromosomal effects rely on labor-intensive
microscopic assessment, the micronucleus (MNi) formation
test is the most widely used method for large-scale
detection of broken or lagging chromosomes [7].
However, because the origins and fates of MNi have
not been completely elucidated [29,30], intra- and
inter-laboratory variability in scoring is still common
[31], and complicates the development of a standard
protocol for quantitative measurement of chromosome loss
rates based on the appearance of MNi. It is also noteworthy
that the MNi assay does not measure the fraction of
drug-arrested cells that undergo mitosis and form viable
aneuploid cells.
This work describes a new assay for measuring CIN
in response to drug treatment that overcomes the
limitations of current approaches. The assay is based
on quantitative measurements of mitotic loss rates of
a nonessential human artificial chromosome (HAC)
carrying a transgene encoding the green fluorescent
protein (EGFP). Thus, cells that inherit the HAC
fluoresce green, while cells that lack it do not. The
proportion of cells that lose the HAC in response to drugs
is measured using FACS, which allows the objective and
accurate assessment of chromosome loss in a large numberof cells (e.g., 106) within minutes. Because only viable cells
are studied, the long-term effects of aneugen exposure on
chromosome loss are readily measured. It is worth noting
that a similar approach but involving natural chromosome
was previously attempted [32], but proved not to be useful
for CIN studies, as the rates of chromosome loss were too
low to be measured accurately. In the present study, the
use of a HAC reporter that is sensitized for chromosome
loss circumvents this problem. The HAC contains a
functional kinetochore and its behavior during mitotic
divisions does not differ from that of normal chromo-
somes [8,10], suggesting that destabilization of natural
chromosomes in response to drug treatment will be
increased proportionally to that observed for the HAC.
As proof of principle, the EGFP/HAC-based assay was
applied to analyze a set of well-known anti-mitotic,
spindle-targeting compounds previously reported to
induce micronucleus formation and chromosome loss.
For each drug, the rate of HAC loss was measured by
flow cytometry and confirmed by FISH analysis. The
most interesting result obtained from these experiments is
the observation that despite their similar cytotoxicity, the
analyzed drugs affect the rates of HAC mis-segregation
during mitotic divisions differently. Moreover, we found
that aneugens with proposed similar mechanisms of
action and cytotoxicity may greatly differ from each
other by their effect on the mitotic stability of the
non-essential human artificial chromosome. Thus, the
assay described here is sensitive enough to discriminate
between drugs with similar mechanisms of action in order
to reveal those with the highest activity on chromosome
stability. In future drug screening studies, taxol exhibiting
the highest effect on HAC stability may be used as a
positive control.
In this work to compare different compounds, the cells
were analyzed 14 days after drug washout. At the same
time, the sampling time for HT1080 cells has a broad
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measured even after 5–7 days without a significant effect
on the calculated rate of HAC loss (see Additional file 1).
For other cell lines, where the EGFP protein is more
stable, the sampling time may be exceeded up to 10–14
days. However, the speed of the assay can be significantly
increased using a modified EGFP with a reduced half-life
(e.g., EGFP with a degron box sequence) that would con-
vert an assay into high-throughput screening. The
transfer of EGFP-HAC into other cell lines will make
possible to assess effects of inhibitors in different
genetic backgrounds such as cell lines harboring mu-
tations in genes that regulate the spindle assembly
checkpoint. It is worth noting that recent innovations
have allowed the generation of HACs with the EGFP
transgene de novo in a broad variety of human cell
lines [33].
This new HAC-based flow cytometry assay may be also
applied for identifying genes controlling chromosome
segregation in human cells because it is more sensitive
to perturbations of spindle assembly and cell cycle
progression than assays based on the analysis of stability
of natural chromosomes [34]. Earlier, the development of
conceptually simple color colony assays in yeast provided
a powerful genetic tool to assess the rates of chromosome
mis-segregation and to identify mutants deficient in this
process [35]. Similarly, in humans, the EGFP/HAC-based
chromosome loss assay may be used to reveal new human
genes involved in chromosome transmission.Conclusions
We have developed a new assay for measuring chromo-
some instability based on the use of a non-essential human
artificial chromosome (HAC) carrying a constitutively
expressed EGFP transgene. This simple assay allows for a
quick and efficient screen of hundreds of drugs to identify
those affecting chromosome mis-segregation. It also
allows ranking of compounds with the same or similar
mechanism of action based on their effect on the rate of
chromosome loss.Additional file
Additional file 1: Figure S1. (A) Micronuclei (MNi) formation (indicated
by arrows) in the HAC-containing HT1080 cells treated by drugs. Scale
bar = 10 μM. (B) The kinetics of MNi formation after drug treatment at
different time points after washout. The experiment was performed for
taxol (10 nM) and nocodazole (1 μM). (C) Rates of HAC loss calculated
using FACS profiles of cells before, after drug treatment and at different
time points after washout. The experiment was performed for taxol and
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